专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007109303A2 FORMULATIONS OF LYMPHOKINES AND METHOD OF USE THEREOF FOR LOCAL OR BOTH LOCAL AND SYSTEMIC CONTROL OF PROLIFERATIVE CELL DISORDERS 审中-公开
标题翻译：淋巴细胞的制剂及其使用方法用于局部或两种局部和系统性控制增殖性细胞疾病
公开(公告)号：WO2007109303A2
公开(公告)日：2007-09-27
申请号：PCT/US2007/006988
申请日：2007-03-20
申请人： PROTHERICS SALT LAKE CITY, INC. , FOWERS, Kirk, D. , ZENTNER, Gaylen, M. , BAUDYS, Miroslav , JUREK, Maria , SAMLOWSKI, Wolfram
发明人： FOWERS, Kirk, D. , ZENTNER, Gaylen, M. , BAUDYS, Miroslav , JUREK, Maria , SAMLOWSKI, Wolfram
IPC分类号： A61K38/20 , A61K9/14
CPC分类号： A61K38/2013 , A61K9/0019 , A61K9/0024 , A61K47/10 , A61K47/34 , C08G63/664 , C08G2261/126 , C08L71/02 , C08L2203/02
摘要： Therapeutic formulations comprising an effective amount of IL-2 or other lymphokine and a biodegradable polymeric carrier having reverse gelation properties and the methods of use thereof for local or both local and systemic control of proliferative cell disorders is disclosed. The formulation can be administered intratumorally/peritumorally and forms an IL-2 containing depot. The IL-2-containing depot provides for continuous, prolonged release of IL-2 sufficient to stimulate the production of cytotoxic T lymphocytes which function both locally and systemically, without causing unacceptable side effects.
摘要翻译：公开了包含有效量的IL-2或其它淋巴因子和具有反向凝胶化特性的可生物降解的聚合物载体的治疗剂型及其用于局部或局部和全身控制增殖性细胞病症的方法。该制剂可以肿瘤内/周围给药并形成含IL-2的贮库。含IL-2的贮存库提供足够的IL-2连续延长释放，以足以刺激局部和全身功能的细胞毒性T淋巴细胞的产生，而不引起不可接受的副作用。

2. 发明申请

WO2002102309A2 FORMULATION OF LYMPHOKINES AND METHOD OF USE THEREOF FOR LOCAL OR BATH LOCAL AND SYSTEMIC CONTROL OF PROLIFERATIVE CELL DISORDERS 审中-公开
标题翻译：淋巴细胞的制备方法及其使用方法，适用于局部或卫生局部及系统性控制增殖性细胞病
公开(公告)号：WO2002102309A2
公开(公告)日：2002-12-27
申请号：PCT/US2002/018807
申请日：2002-06-14
申请人： MACROMED, INCORPORATED , ZENTNER, Gaylen, M. , BAUDYS, Miroslav , JUREK, Maria , SAMLOWSKI, Wolfram
发明人： ZENTNER, Gaylen, M. , BAUDYS, Miroslav , JUREK, Maria , SAMLOWSKI, Wolfram
IPC分类号： A61K
CPC分类号： A61K9/0024 , A61K38/2013 , A61K47/34
摘要： Therapeutic formulations comprising an effective amount of IL-2 or other lymphokine and a biodegradable polymeric carrier having reverse gelation properties and the methods of use thereof for local or both local and systemic control of proliferative cell disorders are disclosed. The formulation can be administered intratumorally/peritumorally and forms an IL-2 containing depot. The IL-2-containing depot provides for continuous, prolonged release of IL-2 sufficient to stimulate the production of cytotoxic T lymphocytes which function both locally and systemically, without causing unacceptable side effects.
摘要翻译：公开了包含有效量的IL-2或其他淋巴因子和具有反向凝胶化特性的可生物降解的聚合物载体的治疗剂型及其用于局部或局部和全身控制增殖性细胞病症的方法。该制剂可以肿瘤内/周围给药并形成含IL-2的贮库。含IL-2的贮存库提供足够的IL-2连续延长释放，以足以刺激局部和全身功能的细胞毒性T淋巴细胞的产生，而不引起不可接受的副作用。

3. 发明申请

WO2002102309A3 FORMULATION OF LYMPHOKINES AND METHOD OF USE THEREOF FOR LOCAL OR BATH LOCAL AND SYSTEMIC CONTROL OF PROLIFERATIVE CELL DISORDERS 审中-公开
公开(公告)号：WO2002102309A3
公开(公告)日：2002-12-27
申请号：PCT/US2002/018807
申请日：2002-06-14
申请人： MACROMED, INCORPORATED , ZENTNER, Gaylen, M. , BAUDYS, Miroslav , JUREK, Maria , SAMLOWSKI, Wolfram
发明人： ZENTNER, Gaylen, M. , BAUDYS, Miroslav , JUREK, Maria , SAMLOWSKI, Wolfram
IPC分类号： C07K14/54
摘要： Therapeutic formulations comprising an effective amount of IL-2 or other lymphokine and a biodegradable polymeric carrier having reverse gelation properties and the methods of use thereof for local or both local and systemic control of proliferative cell disorders are disclosed. The formulation can be administered intratumorally/peritumorally and forms an IL-2 containing depot. The IL-2-containing depot provides for continuous, prolonged release of IL-2 sufficient to stimulate the production of cytotoxic T lymphocytes which function both locally and systemically, without causing unacceptable side effects.

4. 发明申请

WO2007139897A1 COMPOSITIONS AND METHODS FOR THE INHIBITION OF ENDOTHELIAL NITRIC OXIDE SYNTHASE ACTIVITY 审中-公开
标题翻译：抑制内皮素氧化亚合酶活性的组合物和方法
公开(公告)号：WO2007139897A1
公开(公告)日：2007-12-06
申请号：PCT/US2007/012410
申请日：2007-05-23
申请人： UNIVERSITY OF UTAH RESEARCH FOUNDATION , SAMLOWSKI, Wolfram , KONDAPANENI, Muralidhar , MCGREGOR, John, R.
发明人： SAMLOWSKI, Wolfram , KONDAPANENI, Muralidhar , MCGREGOR, John, R.
IPC分类号： A61K31/04 , A61K31/195
CPC分类号： A61K31/04 , A61K31/195
摘要： The present invention relates to the treatment and prevention of the toxic effects associated with increased nitric oxide synthase activity in endothelial cells. In particular, the present invention relates to compounds and methods of treatment that inhibit the nitric oxide synthases present in endothelial cells and methods for treating diseases using such compounds and methods.
摘要翻译：本发明涉及治疗和预防与内皮细胞中一氧化氮合酶活性增加相关的毒性作用。特别地，本发明涉及抑制内皮细胞中存在的一氧化氮合酶的化合物和治疗方法以及使用这些化合物和方法治疗疾病的方法。

5. 发明申请

WO2004080404A2 IL-2 TRANSMEMBRANE CONSTRUCTS 审中-公开
标题翻译： IL-2 TRANSMEMBRANE结构
公开(公告)号：WO2004080404A2
公开(公告)日：2004-09-23
申请号：PCT/US2004/007012
申请日：2004-03-08
申请人： UNIVERSITY OF UTAH RESEARCH FOUNDATION , SAMLOWSKI, Wolfram , ADAMS, Nathan, Bradley , MCGREGOR, John
发明人： SAMLOWSKI, Wolfram , ADAMS, Nathan, Bradley , MCGREGOR, John
IPC分类号： A61K
CPC分类号： C07K14/55 , A61K38/00 , C07K14/70535 , C07K2319/03 , C07K2319/20
摘要： Compounds, genetic constructs, and cancer treatment methods 035 provided. Expression vectors were designed to express fusion genes including hIL-2 with 0 FcT- ? transmembrane anchor derived from 0 subunit of the FC epsilon receptor. mRN 0nd the IL2tm fusion protein was expressed in transfected RD995 tumor cells. Expression of the IL2tm protein on the tumor A511 surface membrane was confirmed by microscopy. RD995 ce11s transfected with IL-2tm or pCMV2b (empty expression vector) were implanted subcutaneously into !3 /HEN mice. Tumors in groups of mice implanted with 10 6 or 10 5 RD995 ce11s transfected with IL-2tm grew slower than controls. Without being limited to any one theory, it is believed that selective expression >f cytokines such as IL-2 on the surface >f tumors is likely to stimulate tumor-infiltrating lymphocytes that are primed and already recognize tumor antigens, enhancing tumor recognition 0nd killing, potentially avoiding toxicity associated with known cytokine therapies.
摘要翻译：提供化合物，遗传构建体和癌症治疗方法035。设计表达载体以表达融合基因，包括hIL-2与来自FCε受体的0亚基的0 FcT-跨膜锚。 mRN 0，IL2tm融合蛋白在转染的RD995肿瘤细胞中表达。通过显微镜证实IL2tm蛋白在肿瘤A511表面膜上的表达。将用IL-2tm或pCMV2b（空表达载体）转染的RD995 ce11s皮下植入！3 / HEN小鼠。植入用IL-2tm转染的10 6或10 5 RD995 ce11s的小鼠组的肿瘤生长慢于对照组。不限于任何一种理论，认为在表面> f肿瘤上的选择性表达> f细胞因子如IL-2可能刺激被引发并已经识别肿瘤抗原的肿瘤浸润性淋巴细胞，增强肿瘤识别第0次杀死，可能避免与已知的细胞因子疗法相关的毒性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式